Abstract
Percutaneous coronary intervention (PCI) in ischemic heart disease is considered one of the most effective methods for reducing complications and improving long-term prognosis. However, in the post-PCI period, two major problems remain: thrombotic complications (restenosis, stent thrombosis) and bleeding events. Therefore, personalization of the duration of antiplatelet therapy is of decisive importance in addressing these issues